Table 2. Clinical characteristics of participants at Debre Markos Comprehensive Specialized Hospital, Northwest Ethiopia (n = 841).
| Variables | Frequency (n) | Percentage (%) |
|---|---|---|
| Baseline OIs | ||
| Yes | 334 | 39.7 |
| No | 507 | 60.3 |
| Baseline nutritional status | ||
| Undernourished | 223 | 26.5 |
| Well-nourished | 618 | 73.5 |
| Functional status | ||
| Working | 702 | 83.5 |
| Ambulatory/ bedridden | 139 | 16.5 |
| Immunodeficiency | ||
| Not significant (CD4 ≥ 500 cells/mm3) | 210 | 25.0 |
| Mild (CD4 = 350–499 cells/mm3) | 171 | 20.3 |
| Advanced (CD4 = 200–349 cells/mm3) | 189 | 22.5 |
| Severe (CD4 <200 cells/mm3) | 271 | 32.2 |
| WHO clinical staging | ||
| Stage I | 370 | 44.0 |
| Stage II | 238 | 28.3 |
| Stage III | 187 | 22.2 |
| Stage IV | 46 | 5.5 |
| Hemoglobin level | ||
| Anaemic (<10 g/dl) | 43 | 5.1 |
| Non-anaemic (≥10 g/dl) | 798 | 94.9 |
| ART eligibility criteria | ||
| Immunological/clinical | 377 | 44.8 |
| Test and treat | 464 | 55.2 |
| Baseline ART regimens | ||
| Efavirenz (EFV)-based | 757 | 90.0 |
| Nevirapine (NVP)-based | 22 | 2.6 |
| Dolutegravir (DGT)-based | 62 | 7.4 |
| ART adherence | ||
| Good | 634 | 75.4 |
| Fair | 25 | 3.0 |
| Poor | 182 | 21.6 |
| ART regimen change | ||
| Yes | 265 | 31.5 |
| No | 576 | 68.5 |
| Taking IPT | ||
| Yes | 528 | 62.8 |
| No | 313 | 37.2 |
| Taking CPT | ||
| Yes | 614 | 73.0 |
| No | 227 | 27.0 |
| ART failure | ||
| Yes | 23 | 2.7 |
| No | 818 | 97.3 |